Jupiter Neurosciences vs Kiora Pharmaceuticals
JUNS and KPRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JUNS and KPRX compare
Kiora Pharmaceuticals is the larger company, worth 3.3 times as much as Jupiter Neurosciences ($4.3M against $1.3M).
Kiora Pharmaceuticals scores higher on the StockData Score (7 against 0 for Jupiter Neurosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JUNS | KPRX |
|---|---|---|
| Size and price | ||
| Market cap | $1.3M | $4.3M |
| Share price | $1.70 | $0.982 |
| Change, 1 year | −98.3% | −55.3% |
| Change, 5 years | – | −99.8% |
| Beta (5Y) | −0.18 | 1.59 |
| Employees | 5 | 3,500 |
| StockData Score | ||
| Total score | 0 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 0.3× |
| FCF yield | – | −198% |
| Profitability | ||
| Return on equity | −1889% | −56.4% (better) |
| Return on invested capital | – | −1374% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −36.0× | – |
| Current ratio | 0.66 | 8.97 (better) |
| Altman Z-score | −23.63 | −9.80 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 2.2% | 25.0% |
| Held by insiders | – | 3.0% |
Go deeper
- JUNS stock overview
- JUNS income statement
- JUNS valuation and score
- KPRX stock overview
- KPRX income statement
- KPRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.